BCL2 (B-cell lymphoma 2) is a core anti-apoptotic regulator that promotes cell survival by antagonizing mitochondrial apoptosis. In follicular lymphoma (FL), the hallmark IGH-BCL2 t(14;18) juxtaposes BCL2 to immunoglobulin regulatory elements, driving BCL2 overexpression and contributing to lymphomagenesis.
Biological significance of BCL2
- Survival advantage in B cells: Transgenic/experimental and clinicopathologic data support that sustained BCL2 expression expands long-lived B-cell pools and facilitates additional oncogenic hits.
- Disease biology in aggressive lymphomas: In DLBCL, BCL2 protein expression is frequent and has been associated with adverse outcomes in multiple cohorts.
Diagnostic utility of BCL2 IHC in hematopathology
BCL2 immunohistochemistry (IHC) is a standard adjunct in hematopathology to support classification and differential diagnosis:
- FL workup: FL classically shows CD10 and BCL2 co-expression, helping distinguish neoplastic follicles from reactive germinal centers (which are typically BCL2-negative by IHC).
- Problem-solving “BCL2-negative” FL: A minority of FL cases are truly BCL2-negative, and some appear negative due to epitope-altering mutations affecting common clones (notably clone 124), where alternative clones (e.g., E17, SP66) may detect BCL2.
Key features of anti-BCL2 IHC antibodies
- Clone/epitope awareness: Literature highlights clone-dependent sensitivity and false-negativity risks; multi-clone strategies can improve detection in select contexts.
- Reproducibility is method-dependent: Multi-laboratory studies show IHC results (including BCL2) vary with platform, protocol, and scoring—supporting rigorous validation and standardized interpretation.
